

**The benefits of using the I-port system on insulin-dependent patients**

Amal M Khan and Khaled A Alswat  
Taif University, Saudi Arabia

**P**atients with insulin-dependent diabetes mellitus (IDDM) show low adherence to insulin injections, which results in poor glycemic control. i-port advance provides a comfortable yet dependable way to inject insulin that allows patients to take multiple daily subcutaneous injections for three days without having to puncture skin for each dose of insulin. Our aim is to evaluate patient satisfaction, glycemic control, and adherence while using this device.

**Methods:** This prospective study examined IDDM patients. Baseline characteristics and diabetes treatment satisfaction questionnaire status (DTSQs) were collected at baseline and at the end of the follow up. All patients were trained to use the i-Port. We divided them into two groups: regular users of the i-Port who used it for >3 months, and irregular users who used it for <3 months. The local complications during use of the i-Port were recorded.

**Results & Discussion:** Of the total of 55 patients, 92.7% had type I diabetes, the mean age was 14.96±8.95, 92.7% were used an insulin pen. The patients were divided into 27 regular users and 28 irregular users. Irregular users had a longer duration of DM ( $p=0.901$ ) at baseline and compared to the regular users, and they were less likely to

report non-compliance with insulin usage ( $p=0.338$ ), more likely to self-inject insulin ( $p=0.038$ ), and had lower HbA1c ( $p=0.056$ ). There was no statistical difference in the mean DTSQs score or the mean glycemic control score between groups. At the end of the follow up, the regular i-port usage improved compliance with insulin usage ( $p=0.028$ ), reduced diabetes-related hospitalization ( $p < 0.001$ ), and reduced the frequency of hypoglycemia ( $p=0.184$ ). Scarring at i-port site was the most common complication.

**Conclusion:** Regular i-Port usage improved compliance and decreased hospitalization and hypoglycemic episodes with a non-significant 0.73% reduction in HbA1c.

**Biography**

Amal M Khan has completed her Bachelor of Medicine Bachelor of Surgery (MBBS) at College of Medicine, Taif University, Taif, KSA. She is an amateur writer, enthusiastic, patient and hard worker Medical Intern. She adores the scientific research and she will contentiously the education in Family Medicine Residency program. She was a speaker at local and international conferences and was Best Young Researchers for oral presentation at the 14th international conference and exhibition on targeting diabetes and novel therapeutic, Malaysia. She has published a lot of researches in a field of diabetes. She has attended and participated at a lot of conference and workshop in endocrinology and medical field

dr.amal-khan@msn.com

Notes: